Pancreatic cancer that is locally advanced and nonresectable is often treated with a combination of chemotherapy and radiation therapy (chemoradiotherapy, or CRT). Multivariate analysis identified 3 factors that can be used to separate patients into 3 prognostic groups. The authors are from the National Cancer Center Hospital in Tokyo.
Independent prognostic factors identified by multivariate analysis:
(1) ECOG Performance Status
(2) regional lymph nodes
(3) serum CA 19-9
Parameter |
Finding |
Points |
---|---|---|
ECOG performance status |
0 (no symptoms) |
0 |
|
1 (symptomatic but ambulatory) |
0 |
|
2 (bedridden < 50% of day) |
1 |
|
3 (bedridden >= 50% of day) |
NA |
|
4 (incapacitated) |
NA |
regional lymph nodes |
not enlarged (swelling absent) |
0 |
|
enlarged (swelling present) |
1 |
serum CA 19-9 |
< 1,000 U/mL |
0 |
|
>= 1,000 U/mL |
1 |
from second column, page 492
where:
• The index would not apply for a person with ECOG performance status of 3 or 4, as the disease is too advanced and prognosis is poor.
• The normal reference range for serum CA 19-9 is not given.
Parameter |
Hazard Ratio |
95% CI |
p value |
---|---|---|---|
performance status 2 |
8.15 |
2.88 – 23.09 |
< 0.01 |
regional lymph node swelling |
2.83 |
1.45 - 5.49 |
< 0.01 |
CA 19-9 >= 1,000 U/mL |
2.17 |
1.14 – 4.12 |
0.02 |
from Table 3 page 494
prognostic index =
= (2.10 * (points for performance status)) + (1.04 * (points for regional lymph nodes)) + (0.77 * (points for CA 19-9))
Interpretation:
• minimum index: 0
• maximum score: 3.91
•The higher the score, the shorter the survival
Prognostic Index |
Group |
Median Survival in Days |
---|---|---|
< 0.7 |
A |
410 |
0.7 to 1.79 |
B |
239 |
>= 1.8 |
C |
143 |
from column 1, page 494
Purpose: To evaluate a patient with locally advanced, unresectable pancreatic cancer using the prognostic index of Ikeda et al.
Specialty: Hematology Oncology, Surgery, general, Gastroenterology
Objective: severity, prognosis, stage
ICD-10: C25,